You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Rochester, Minnesota 55905

  • Lymphoma


The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).

Study summary:

Patients with B-cell NHL that comes back after chemotherapy are typically treated with cisplatin, high-dose cytosine arabinoside and dexamethasone (DHAP) or other platinum-based treatments. Recent studies have shown a 37% response rate in patients with large cell lymphoma to immunotherapy with Rituxan. Patients <75 years old and in otherwise good health may be candidates for high dose therapy with stem cell rescue if they have disease that remains sensitive to chemotherapy. Typically, patients are administered 2 cycles of DHAP or ICE (ifosfamide, carboplatin, and etoposide) and, if the disease responds, they proceed to high-dose therapy with stem cell support. Even patients not considered transplant candidates are also often treated with DHAP or ICE or other salvage regimens. It is likely that the response rate with DHAP alone in patients eligible for transplant is <59%. Recent studies have attempted to improve on the results from DHAP or ICE by combining them with rituxan. NCCTG has just completed a phase II trial of R-DHAP. Preliminary results of the R-ICE protocol indicate a higher response rate and longer time to progression than traditional ICE. The problem with DHAP and ICE is that they are associated with significant side effects and specifically, with DHAP the cisplatin often causes kidney problems. In fact, some patients who are considered transplant eligible before DHAP may become transplant ineligible simply by the kidney side effects. Clearly, there is a need to improve the quality of life of patients undergoing treatment and to avoid the kidney problems.


Inclusion Criteria: - Patients with any stage (I-IV, including those with bone marrow involvement) relapsed CD20+ B-cell non-Hodgkins lymphoma, within 5 years, with aggressive histology who have not responded to, or relapsed after, initial chemotherapy and would, if treated off-study, be treated with a platinum-containing regimen. - CD20+ diffuse large cell, mantle cell, or transformed histologies are eligible. - Tumor biopsy to demonstrate histology < = 6 weeks prior to registration. Computed tomography (CT) or ultrasound guided needle biopsies are acceptable as long as the pathologists can confirm histology and the CD20 positivity of the tumor. - Measurable disease (to be considered measurable the lesion must be greater than or equal to 1.5 x 1.5 cm). - Greater than or equal to 18 years of age. - ECOG performance status (PS) 0, 1, or 2. - Limited to one prior chemotherapy regimen. Antibody therapy alone or immunotherapy alone will not count as a prior regimen - only chemotherapy regimens (for example - RCHOP, CVP, etc.). External beam radiation therapy does not count as a regimen. - The following laboratory values obtained less than or equal to 14 days prior to registration: - Absolute neutrophil count (ANC) greater than or equal to 1500 - Platelets (PLT) greater than or equal to 75,000 - Total bilirubin less than or equal to 2 mg/dL - Creatinine less than or equal to 1.5 x upper normal limit (UNL) Exclusion Criteria: - Any of the following as this regimen may be harmful to a developing fetus or nursing child: - Pregnant women - Nursing women - Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) - HIV infection. - Prior chemotherapy or biologic therapy <= 4 weeks prior to registration . - Persistent acute toxicities due to prior chemotherapy or biologic therapy. - Active malignancies other than NHL. - Central nervous system (CNS) lymphoma. - Any of the following comorbid conditions: - Uncontrolled diabetes mellitus - Uncontrolled hypertension - Uncontrolled peptic ulcer disease - Uncontrolled infection



Primary Contact:

Principal Investigator
Patrick B. Johnston, M.D., Ph.D.
Mayo Clinic

Backup Contact:


Location Contact:

Rochester, Minnesota 55905
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.